Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 92-100

  Fujita, Tetsuo ^a,d   Satoh, Takefumi ^a,e   Timme, Terry L ^a,b   Hirayama, Takahiro ^c   Zhu, Julie X ^a   Kusaka, Nobuyuki ^a,f   Naruishi, Koji ^a,f   Yang, Guang ^c   Goltsov, Alexei ^c   Wang, Jianxiang ^c   Vlachaki, Maria T ^a,b,g   Teh, Bin S ^a,h   Brian Butler, E ^a,h   Thompson, Timothy C ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Bladder cancer; Gene therapy; GLIPR1; Prostate cancer; Radiation therapy

Indexed keywords

ADENOVIRAL VECTOR MEDIATED GLIOMA PATHOGENESIS RELATED PROTEIN 1; ADENOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; COLONY FORMATION; CONTROLLED STUDY; DRUG DOSE ESCALATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; THERAPY EFFECT; TREATMENT DURATION; TUMOR GROWTH;

BLADDER CANCER; GENE THERAPY; GLIPR1; PROSTATE CANCER; RADIATION THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892551595     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.10.007     Document Type: Article

References (30)

1. Hanks G.E., Lee W.R., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen>or = 10ng/ml. Int J Radiat Oncol Biol Phys 1996, 35:861-868.
2. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 39:1011-1018.
3. Gao Y., Ishiyama H., Sun M., Brinkman K.L., Wang X., Zhu J., et al. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol 2011, 6:39.
4. Goldsmith B., Tucker K., Conway R.G., He J., Guzzo T., Bekelman J., et al. Discordance between preoperative and postoperative bladder cancer location: implications for partial-bladder radiation. Int J Radiat Oncol Biol Phys 2012, [in press]. Available online July 3, 2012.
5. Chhikara M., Huang H., Vlachaki M.T., Zhu X., Teh B., Chiu K.J., et al. Enhanced therapeutic effect of HSV-tk + GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001, 3:536-542.
6. Teh B.S., Aguilar-Cordova E., Kernen K., Chou C.C., Shalev M., Vlachaki M.T., et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int J Radiat Oncol Biol Phys 2001, 51:605-613.
7. Teh B.S., Ayala G., Aguilar L., Mai W.Y., Timme T.L., Vlachaki M.T., et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 2004, 58:1520-1529.
8. Gibbs G.M., Roelants K., O'Bryan M.K. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense. Endocr Rev 2008, 29:865-897.
9. Tabata K., Kurosaka S., Watanabe M., Edamura K., Satoh T., Yang G., et al. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 2011, 18:969-978.
10. Ren C., Li L., Goltsov A.A., Timme T.L., Tahir S.A., Wang J., et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002, 22:3345-3357.
11. Ren C., Li L., Yang G., Timme T.L., Goltsov A., Ji X., et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004, 64:969-976.
12. Li L., Abdel Fattah E., Cao G., Ren C., Yang G., Goltsov A.A., et al. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 2008, 68:434-443.
13. Li L., Ren C., Yang G., Fattah E.A., Goltsov A.A., Kim S.M., et al. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 2011, 71:7694-7704.
14. Satoh T., Timme T.L., Saika T., Ebara S., Yang G., Wang J., et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003, 14:91-101.
15. Naruishi K., Timme T.L., Kusaka N., Fujita T., Yang G., Goltsov A., et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 2006, 13:658-663.
16. Sonpavde G., Thompson T.C., Jain R.K., Ayala G.E., Kurosaka S., Edamura K., et al. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 2011, An Official Journal of the American Association for Cancer Research.
17. Shaker M.R., Yang G., Timme T.L., Park S.H., Kadmon D., Ren C., et al. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 2000, 18:429-438.
18. Fujita T., Timme T.L., Tabata K., Naruishi K., Kusaka N., Watanabe M., et al. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 2007, 14:227-236.
19. Vlachaki M.T., Chhikara M., Aguilar L., Zhu X., Chiu K.J., Woo S., et al. Enhanced therapeutic effect of multiple injections of HSV-TK+GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 2001, 51:1008-1017.
20. Janik P., Briand P., Hartmann N.R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 1975, 35:3698-3704.
21. Nasu Y., Bangma C.H., Hull G.W., Lee H.M., Hu J., Wang J., et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 1999, 6:338-349.
22. Yang G., Goltsov A.A., Ren C., Kurosaka S., Edamura K., Logothetis R., et al. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 2012, 10(2):218-219.
23. Lohr F., Hu K., Haroon Z., Samulski T.V., Huang Q., Beaty J., et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000, 2:195-203.
24. Sasaki R., Shirakawa T., Zhang Z.J., Tamekane A., Matsumoto A., Sugimura K., et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001, 51:1336-1345.
25. Freytag S.O., Paielli D., Wing M., Rogulski K., Brown S., Kolozsvary A., et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002, 54:873-885.
26. Oh Y.T., Chen D.W., Dougherty G.J., McBride W.H. Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model. Int J Radiat Oncol Biol Phys 2004, 59:579-583.
27. van Bokhoven A., Varella-Garcia M., Korch C., Miller G.J. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001, 61:6340-6344.
28. Zeng M., Cerniglia G.J., Eck S.L., Stevens C.W. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 1997, 8:1025-1032.
29. Simons J.W., Marshall F.F. The future of gene therapy in the treatment of urologic malignancies. Urol Clin North Am 1998, 25:23-38.
30. Teh B.S., Aguilar-Cordova E., Vlachaki M.T., Aguilar L., Mai W.Y., Caillouet J., et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 2002, 7:458-466.